fda takes tirzepatide off shortage list Compounders lose battle over Eli Lilly weight loss drug and Tirzepatide OFF FDA shortage list.

ResMed: GLP-1 Threats Are Overstated Summary My contrarian take on ResMed is that GLP-1 concerns are overstated, and even though a portion of market share will be lost, the remaining portion will be more beneficial to profitability

Weight loss effectiveness and side effect risks for oral Wegovy are comparable to the injectable formulation

Patients are recommended to cease the administration of GLP-1 agonists, such as semaglutide, a fortnight before the procedure, to reduce potential complications stemming from impaired gastric emptying

They may opt to monitor you more closely for any side effects of these oral drugs and assess their effectiveness

Amini A, Ajani J, Komaki R, Allen PK, Minsky BD, Blum M, Xiao L, Suzuki A, Hofstetter W , Swisher S, Gomez D, Liao Z, Lee JH, Bhutani MS, Welsh JW